Potential use of nanostructured lipid carriers for topical delivery of flurbiprofen

Journal of Pharmaceutical Sciences

Volumn 100, Issue 1, 2011, Pages 242-251

  Gonzalez Mira E ^a   Nikolic S ^a   Garcia M L ^a   Egea, M A ^a   Souto, E B ^b,c   Calpena, A C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b UNIVERSIDADE FERNANDO PESSOA   (Portugal)

^c UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

Author keywords

Draize test; Flurbiprofen; Nanoparticles; Nanostructured lipid carriers; Percutaneous; Pharmacokinetics; Polymorphism; Skin; SKINTEX test; X ray powder diffractometry

Indexed keywords

CASTOR OIL; DRUG CARRIER; FATTY ACID; FLURBIPROFEN; GLYCEROL BEHENATE; LIPID; NANOMATERIAL; STEARIC ACID; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG PENETRATION; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; SKIN TEST; X RAY DIFFRACTION;

EID: 78650050887     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22271     Document Type: Article

References (40)

1. Williams AC. 2003. Transdermal and topical drug delivery: From theory to clinical practice, 1st edition. London: PharmPress. p 27-48.
2. Souto EB, Mehnert W, Muller RH. 2006. Polymorphic behaviour of Compritol (R) 888 ATO as bulk lipid and as SLN and NLC. J Microencapsul 23: 417-433.
3. Souto EB. 2005. SLN and NLC for topical delivery of antifungals. PhD thesis.
4. Müller RH, Radtke M, Wissing SA. 2002. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54: 131-155.
5. Doktorovova S, Araujo J, Garcia ML, Rakovsky E, Souto EB. 2010. Formulating fluticasone propionate in novel PEG-containing nanostructured lipid carriers (PEG-NLC). Colloids Surf B: Biointerf 75: 538-542.
6. Joshi MD, Müller RH. 2009. Lipid nanoparticles for parenteral delivery of actives. Eur J Pharm Biopharm 71: 161-172.
7. Lin Y, Huang Z, Zhuo R, Fang J. 2010. Combination of calcipotriol and methotrexate in nanostructured lipid carriers for topical delivery. Int J Nanomed 5: 117-128.
8. Müller RH, Petersen RD, Hommoss A, Pardeike J. 2007. Nanostructured lipid carriers (NLC) in cosmetic dermal products. Adv Drug Deliv Rev 59: 522-530.
9. Bhaskar K, Anbu J, Ravichandiran V, Venkateswarlu V, Rao YM. 2009. Lipid nanoparticles for transdermal delivery of flurbiprofen: Formulation, in vitro, ex vivo and in vivo studies. Lipids Health Dis 8: 6.
10. Luykx DM, Peters RJ, van Ruth SM, Bouwmeester H. 2008. A review of analytical methods for the identification and characterization of nano delivery systems in food. J Agric Food Chem 56: 8231-8247.
11. Deshiikan SR, Papadopoulos KD. 1998. Modified Booth equation for the calculation of zeta potential. Colloid Polym Sci 276: 117-124.
12. Gamisans F. 1999. Estudio fisicoquímico de la asociación de flurbiprofeno a sistemas poliméricos biodegradables. PhD thesis.
13. Vega E, Gamisans F, Garcia ML, Chauvet A, Lacoulonche F, Egea MA. 2008. PLGA nanospheres for the ocular delivery of flurbiprofen: Drug release and interactions. J Pharm Sci 97: 5306-5317.
14. Vega E, Egea MA, Valls O, Espina M, Garcia ML. 2006. Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. J Pharm Sci 95: 2393-2405.
15. Westesen K, Bunjes H, Koch MHJ. 1997. Physicochemical characterization of lipid nanoparticles and evaluation of their drug loading capacity and sustained release potential. J Control Release 48: 223-236.
16. OECD. 2004. Paris, France. Guideline for the Testing of Chemicals. No 428: Skin Absorption: In Vitro Method.
17. ECVAM. 2008. Test guideline for Skin Absorption: In Vitro Method. Official Journal of the European Union Method B.45 of Annex to 440/2008/EC (EU Test Methods Regulation) and its Corrigendum.
18. Escribano E, Calpena AC, Queralt J, Obach R, Domenech J. 2003. Assessment of diclofenac permeation with different formulations: Anti-inflammatory study of a selected formula. Eur J Pharm Sci 19: 203-210.
19. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, Yang Y, Xu H, Yang X. 2006. Podophyllotoxin-loaded solid lipid nanoparticles for epidermal targeting. J Control Release 110: 296-306.
20. Calpena AC, Lauroba J, Suriol M, Obach R, Domenech J. 1994. Effect of d-limonene on the transdermal permeation of nifedipine and domperidone. Int J Pharm 103: 179-186.
21. Ma X, Fang L, Guo J, Zhao N, He Z. 2009. Effect of counter-ions and penetration enhancers on the skin permeation of flurbiprofen. J Pharm Sci 99: 1826-1837.
22. Welss T, Basketter DA, Schröder KR. 2004. In vitro skin irritation: Facts and future. State of the art review of mechanisms and models. Toxicol Vitro 18: 231-243.
23. Zafarizal Aldrin AH, Rosnah I, Salmiah A. 2005. Safety evaluation for dermal and ocular irritation of palm dihidroxystearic acid as a cosmetics ingredient. J Oil Palm Res 17: 160-167.
24. Bason MM, Harvell J, Realica B, Gordon V, Maibach HI. 1992. Comparison of in vitro and human in vivo dermal irritancy data for four primary irritants. Toxicol Vitro 6: 383-387.
25. OECD. 2002. Guideline for the Testing of Chemicals. No 404: Acute Dermal Irritation/Corrosion.
26. Draize JH, Woodard G, Calvery HO. 1944. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther 82: 377-390.
27. Passantino A. 2008. Application of the 3Rs principles for animals used for experiments at the beggining of the 21st century. Annu Rev Biomed Sci 10: 27-32.
28. Leardi R. 2009. Experimental design in chemistry: A tutorial. Anal Chim Acta 652: 161-172.
29. Williams AC, Cornwell PA, Barry BW. 1992. On the non-Gaussian distribution of human skin permeabilities. Int J Pharm 86: 69-77.
30. Kuntsche J, Bunjes H, Fahr A, Pappinen S, Rönkkö S, Suhonen M, Urtti A. 2008. Interaction of lipid nanoparticles with human epidermis and an organotypic cell culture model. Int J Pharm 354: 180-195.
31. Wissing S, Lippacher A, Muller R. 2001. Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci 52: 313-324.
32. Pathak P, Nagarsenker M. 2009. Formulation and evaluation of lidocaine lipid nanosystems for dermal delivery. AAPS PharmSciTech 10: 985-992.
33. Aarons L, Salisbury R, Alam-Siddiqi M, Taylor L, Grennan DM. 1986. Plasma and synovial fluid kinetics of flurbiprofen in rheumatoid arthritis. Br J Clin Pharm 21: 155-163.
34. Ozbay L, Unal DO, Cakici I, Fenercioglu A, Erol D. 2009. Clinical study on the bioequivalence of two tablet formulations of flurbiprofen. Eur J Drug Metab Pharmacokinet 34: 1-5.
35. Cardoe N. 1977. A double-blind crossover study to compare the efficacy of three dosage levels of flurbiprofen in the treatment of rheumatoid disease and osteoarthrosis. Curr Med Res Opin 5: 99-105.
36. Davies NM. 1995. Clinical pharmacokinetics of flurbiprofen and its enantiomers. Clin Pharmacokinet 28: 100-114.
37. Westesen K. 1993. Investigations on the physical state of lipid nanoparticles by synchrotron radiation X-ray diffraction. Int J Pharm 93: 189-199.
38. Jenning V, Schäfer-Korting M, Gohla S. 2000. Vitamin A-loaded solid lipid nanoparticles for topical use: Drug release properties. J Control Release 66: 115-126.
39. Moreno E, Cordobilla R, Calvet T, Cuevas-Diarte MA, Gbabode G, Negrier P, Mondieig D, Oonk HAJ. 2007. Polymorphism of even saturated carboxylic acids from n-decanoic to n-eicosanoic acid. New J Chem 31: 947-957.
40. Kaneko F. 2001. Polymorphism and phase transitions of fatty acids and acylglycerols. In: Garti N, Sato K, editors. Crystallization processes in fats and lipid systems. New York: Marcel Dekker. pp 53-97.